Literature DB >> 28123561

A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs.

Sara Pizzamiglio1, Susanna Zanutto2, Chiara M Ciniselli3, Antonino Belfiore4, Stefano Bottelli1, Manuela Gariboldi2, Paolo Verderio1.   

Abstract

Circulating microRNAs (miRNAs) are promising non-invasive biomarkers whose expression may be affected by confounding factors, including hemolysis, that should be considered in studies of miRNA discovery. The present study proposes a methodology for evaluating the impact of hemolysis on the expression of miRNAs. An experiment of in vitro controlled hemolysis was designed for assessing if changes in the expression of eight miRNAs observed to be circulating in plasma may be associated with hemolysis, and also to estimate the level of red blood cell (RBC) contamination in plasma samples where the expression of these miRNAs will be measured. It was confirmed that four miRNAs, miR-16, miR-92a, miR-451 and miR-486, known to be present in blood cells, were influenced by contamination of RBCs. Furthermore, it was demonstrated that miR-378 and miR-30c are hemolysis-independent and that the expression of miR-320 and miR-324-3p was associated with the level of RBC contamination. This procedure is proposed as a tool for the evaluation of the influence of hemolysis on candidate circulating miRNA biomarkers prior to their analysis in plasma samples.

Entities:  

Keywords:  circulating microRNA; hemolysis; plasma

Year:  2016        PMID: 28123561      PMCID: PMC5244842          DOI: 10.3892/ol.2016.5452

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A normalization strategy for the analysis of plasma microRNA qPCR data in colorectal cancer.

Authors:  Sara Pizzamiglio; Stefano Bottelli; Chiara Maura Ciniselli; Susanna Zanutto; Claudia Bertan; Manuela Gariboldi; Marco Alessandro Pierotti; Paolo Verderio
Journal:  Int J Cancer       Date:  2013-10-22       Impact factor: 7.396

3.  NqA: an R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data.

Authors:  Paolo Verderio; Stefano Bottelli; Chiara Maura Ciniselli; Marco Alessandro Pierotti; Manuela Gariboldi; Sara Pizzamiglio
Journal:  Anal Biochem       Date:  2014-06-02       Impact factor: 3.365

4.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

Authors:  Gabriella Sozzi; Mattia Boeri; Marta Rossi; Carla Verri; Paola Suatoni; Francesca Bravi; Luca Roz; Davide Conte; Michela Grassi; Nicola Sverzellati; Alfonso Marchiano; Eva Negri; Carlo La Vecchia; Ugo Pastorino
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

5.  Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.

Authors:  Colin C Pritchard; Evan Kroh; Brent Wood; Jason D Arroyo; Katy J Dougherty; Melanie M Miyaji; Jonathan F Tait; Muneesh Tewari
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-12

6.  A lipemia-independent NanoDrop(®)-based score to identify hemolysis in plasma and serum samples.

Authors:  Valentina Appierto; Maurizio Callari; Elena Cavadini; Daniele Morelli; Maria Grazia Daidone; Paola Tiberio
Journal:  Bioanalysis       Date:  2014-05       Impact factor: 2.681

7.  The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Authors:  Michaela B Kirschner; J James B Edelman; Steven C-H Kao; Michael P Vallely; Nico van Zandwijk; Glen Reid
Journal:  Front Genet       Date:  2013-05-24       Impact factor: 4.599

8.  Haemolysis during sample preparation alters microRNA content of plasma.

Authors:  Michaela B Kirschner; Steven C Kao; J James Edelman; Nicola J Armstrong; Michael P Vallely; Nico van Zandwijk; Glen Reid
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

9.  Technical factors involved in the measurement of circulating microRNA biomarkers for the detection of colorectal neoplasia.

Authors:  Atsushi Yamada; Mary A Cox; Kristin A Gaffney; Amber Moreland; C Richard Boland; Ajay Goel
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

10.  Pre-profiling factors influencing serum microRNA levels.

Authors:  Sara A MacLellan; Calum MacAulay; Stephen Lam; Cathie Garnis
Journal:  BMC Clin Pathol       Date:  2014-06-21
View more
  20 in total

Review 1.  Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.

Authors:  José Luis García-Giménez; Marta Seco-Cervera; Trygve O Tollefsbol; Carlos Romá-Mateo; Lorena Peiró-Chova; Pablo Lapunzina; Federico V Pallardó
Journal:  Crit Rev Clin Lab Sci       Date:  2017-12-11       Impact factor: 6.250

2.  Expression of microRNAs in human platelet-poor plasma: analysis of the factors affecting their expression and association with proximal genetic variants.

Authors:  Alba Rodriguez-Rius; Angel Martinez-Perez; Sonia López; Maria Sabater-Lleal; Juan Carlos Souto; José Manuel Soria
Journal:  Epigenetics       Date:  2020-06-24       Impact factor: 4.528

3.  Commercially Available Blocking Oligonucleotides Effectively Suppress Unwanted Hemolysis-Related miRNAs in a Large Whole-Blood RNA Cohort.

Authors:  Jenna LaBelle; Mark Bowser; Alison Brown; Leanna Farnam; Alvin Kho; Jiang Li; Michael McGeachie; Robert Chase; Shannon Piehl; Kevin Allen; Brian D Hobbs; Scott T Weiss; Craig Hersh; Kelan Tantisira; Sami S Amr
Journal:  J Mol Diagn       Date:  2021-04-17       Impact factor: 5.341

4.  Combination of RERG and ZNF671 methylation rates in circulating cell-free DNA: A novel biomarker for screening of nasopharyngeal carcinoma.

Authors:  Yifei Xu; Weilin Zhao; Yingxi Mo; Ning Ma; Kaoru Midorikawa; Hatasu Kobayashi; Yusuke Hiraku; Shinji Oikawa; Zhe Zhang; Guangwu Huang; Kazuhiko Takeuchi; Mariko Murata
Journal:  Cancer Sci       Date:  2020-05-19       Impact factor: 6.716

5.  Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.

Authors:  Daniel Gilbert Weber; Alexander Brik; Swaantje Casjens; Katarzyna Burek; Martin Lehnert; Beate Pesch; Dirk Taeger; Thomas Brüning; Georg Johnen
Journal:  BMC Res Notes       Date:  2019-02-11

6.  Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis.

Authors:  Mette Pernille Myklebust; Benedikte Rosenlund; Peder Gjengstø; Bogdan Stefan Bercea; Ása Karlsdottir; Marianne Brydøy; Olav Dahl
Journal:  Front Genet       Date:  2019-05-22       Impact factor: 4.599

7.  Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus.

Authors:  Karen Chiam; George C Mayne; Tingting Wang; David I Watson; Tanya S Irvine; Tim Bright; Lorelle T Smith; Imogen A Ball; Joanne M Bowen; Dorothy M Keefe; Sarah K Thompson; Damian J Hussey
Journal:  World J Gastroenterol       Date:  2020-05-28       Impact factor: 5.742

8.  Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples.

Authors:  Pamela R Matias-Garcia; Rory Wilson; Veronika Mussack; Eva Reischl; Melanie Waldenberger; Christian Gieger; Gabriele Anton; Annette Peters; Andrea Kuehn-Steven
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

9.  Expression profile of plasma microRNAs and their roles in diagnosis of mild to severe traumatic brain injury.

Authors:  Xiaojing Qin; Lingzhi Li; Qi Lv; Qingming Shu; Yongliang Zhang; Yaping Wang
Journal:  PLoS One       Date:  2018-09-18       Impact factor: 3.240

10.  Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy.

Authors:  Kazuki Heishima; Travis Meuten; Kyoko Yoshida; Takashi Mori; Douglas H Thamm
Journal:  BMC Vet Res       Date:  2019-01-25       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.